ThomasC.BlevinsMD
Endocrinology • Austin, TXDiabetes, Lipid Metabolism
Endocrinologist, Texas Diabetes & Endocrinology
Dr. Blevins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
6500 North Mo Pac Expressway
Building 3, Suite 200
Austin, TX 78731Phone+1 512-458-8400Fax+1 512-458-8593- Is this information wrong?
Education & Training
Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 1984 - 1986- Baylor College of MedicineResidency, Internal Medicine, 1981 - 1984
- Baylor College of MedicineClass of 1981
Certifications & Licensure
TX State Medical License 1981 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Diabetes Recognition Program National Committee for Quality Assurance, 2012-2015
- Super Doctor SuperDoctors.com
- Join now to see all
Clinical Trials
- A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port Start of enrollment: 2006 Oct 01
- Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port Start of enrollment: 2009 Aug 01
- A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes Start of enrollment: 2014 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsBeneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 Diabetes.Raghinaru, D., Desjardins, D., Levister, C., O'Malley, G., Reid, C., Lum, J., Kollman, C., Beck, R., Levy, C., Kudva, Y., Pandit, K., Blevins, T., Casaubon, L.> ;Clinical Diabetes. 2024 Jan 1
- 28 citationsDaily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.Sean Wharton, Thomas Blevins, Lisa Connery, Julio Rosenstock, Sohini Raha, Rong Liu, Xiaosu Ma, Kieren J Mather, Axel Haupt, Deborah Robins, Edward Pratt, Christof Kaz...> ;The New England Journal of Medicine. 2023 Sep 7
- 2 citationsBreaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes.Simon Heller, João Filipe Raposo, Santiago Tofé, Wasim Hanif, Zbynek Schroner, Su Down, Thomas Blevins> ;Clinical Diabetes. 2023 Jan 1
- Join now to see all
Journal Articles
- Efficacy and Safety of MYL‐1501D Versus Insulin Glargine in Patients with Type 2 Diabetes After 24 Weeks: Results of the Phase 3 INSTRIDE 2 StudyThomas Blevins, MD, Diabetes, Obesity and Metabolism
Press Mentions
Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes AssociationJune 25th, 2021- Mylan and Biocon Biologics Announce Launch of Semglee™ (Insulin Glargine Injection) in the U.S. To Expand Access for Patients Living with DiabetesAugust 31st, 2020
Ideal Protein Announces Inaugural Medical Advisory BoardApril 12th, 2016- Join now to see all
Professional Memberships
- Fellow
Hospital Affiliations
Ascension Seton Medical Center AustinAustin, Texas
St. David's Medical CenterAustin, Texas- CHRISTUS Santa Rosa Hospital - San MarcosSan Marcos, Texas
Baylor Scott & White Medical Center - TempleTemple, Texas- Baylor Scott & White Medical Center - TempleTemple, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
